Psoriasis

Editor's Choice

Golimumab eases PsA: Benefits of once-monthly anti-TNF treatment sustained for at least two years

Results have been analyzed from 276 patients followed for two years in the phase 3 trial of golimumab for the treatment of psoriatic arthritis. The data shows sustained benefits with no new safety signals emerging.

LATEST ARTICLES

’Crystel’ clear: Study shows etanercept improves depression, anxiety in psoriasis patients

International report — Etanercept therapy helps to improve symptoms of depression and anxiety long-term in patients suffering from moderate-to severe psoriasis, according to the results of the Crystel study.

All systems go: Association between psoriasis, metabolic syndrome is strong

The evidence linking psoriasis to metabolic syndrome and cardiovascular disease is overwhelming, classifying psoriasis as a systemic disease and not simply a disease of the skin.

Golimumab eases PsA: Benefits of once-monthly anti-TNF treatment sustained for at least two years

Unraveling psoriasis: Basic science, clinical research provide new insights on immunologic basis

Findings from multiple types of studies point to IL-23 as a master cytokine in the pathogenesis of psoriasis.

Treating psoriatic arthritis: One-year data positive for sustained, significant benefits of golimumab

The investigational anti-tumor necrosis factor (TNF) monoclonal antibody golimumab (Centocor) is being evaluated as a once-a-month subcutaneous injection for the treatment of psoriatic arthritis in a Phase 3 trial that enrolled approximately 400 patients.